January 2026
PTSD
What January 2026's 8 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research published in January 2026 on PTSD spans diverse interventions and outcomes. A large RCT found no overall benefit of ketamine over placebo, though a machine-learning model using DNA methylation predicted responders with 92.9% accuracy. Preclinical work in rats suggests nitrous oxide may reduce anxiety and enhance neurogenesis, while case reports and series hint at benefits from yogic practices and oral dextromethorphan, but also warn of potential adverse effects such as new-onset OCD after MDMA-assisted therapy. Overall, the evidence is mixed and largely preliminary, with many studies being small, uncontrolled, or ongoing.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Nitrous oxide promotes exploratory activity and stimulates neurogenesis in a male rat model of post-traumatic stress disorder. 2026 | preclinical animal study | Supports | Nitrous oxide exposure reduced anxiety-related symptoms and enhanced hippocampal neurogenesis in rats with PTSD-like behavior induced by single prolonged stress. | |
| EFFECT OF CYCLIC RAJYOGA MEDITATION AND BHRAMARI PRANAYAMA IN THE MANAGEMENT OF CHITTODWEGA (POST-TRAUMATIC STRESS DIS-ORDER): A CASE STUDY 2026 | case study | 1 | Supports | A 15-day yogic intervention reduced stress, agitation, fear, intrusive thoughts, and sleep disturbances in a woman with trauma-related symptoms resembling PTSD. |
| Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD. 2026 | randomized controlled trial | Mixed | The CAP-ketamine trial found no overall benefit of ketamine over placebo, but a methylation-derived score distinguished responders with 92.9% accuracy. | |
| Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker. 2026 | observational cohort with experimental component | Mixed | Participants with MDE+PTSD had significantly lower baseline copeptin levels and a blunted reduction post-ketamine compared to MDE-only, suggesting altered vasopressinergic function. | |
| New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report 2026 | case study | 1 | Opposes | MDMA-assisted psychotherapy was associated with new-onset obsessive-compulsive disorder in a patient with prior nondistressing compulsions, though PTSD symptoms improved. |
| Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study 2026 | survey study | 243 | Mixed | 31.3% of participants met DSM-5 criteria for PTSD, with avoidance predicting greater and acceptance predicting lower symptom severity. |
| Case Report: Oral glutamatergic augmentation for trauma-related disorders with fluoxetine-/bupropion-potentiated dextromethorphan ± piracetam: a four-patient case series. 2026 | case series | 4 | Supports | An oral dextromethorphan-based protocol potentiated by fluoxetine produced clinically meaningful symptom improvement within days to weeks in four patients, with no documented dissociation, hypertension, or mania. |
| Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol. 2026 | double-blind, placebo-controlled, randomized controlled trial | 60 | Unclear | This trial is ongoing; no results are reported in the abstract. |
Nitrous oxide exposure reduced anxiety-related symptoms and enhanced hippocampal neurogenesis in rats with PTSD-like behavior induced by single prolonged stress.
preclinical animal study
A 15-day yogic intervention reduced stress, agitation, fear, intrusive thoughts, and sleep disturbances in a woman with trauma-related symptoms resembling PTSD.
case study Sample size: 1
The CAP-ketamine trial found no overall benefit of ketamine over placebo, but a methylation-derived score distinguished responders with 92.9% accuracy.
randomized controlled trial
Participants with MDE+PTSD had significantly lower baseline copeptin levels and a blunted reduction post-ketamine compared to MDE-only, suggesting altered vasopressinergic function.
observational cohort with experimental component
MDMA-assisted psychotherapy was associated with new-onset obsessive-compulsive disorder in a patient with prior nondistressing compulsions, though PTSD symptoms improved.
case study Sample size: 1
31.3% of participants met DSM-5 criteria for PTSD, with avoidance predicting greater and acceptance predicting lower symptom severity.
survey study Sample size: 243
An oral dextromethorphan-based protocol potentiated by fluoxetine produced clinically meaningful symptom improvement within days to weeks in four patients, with no documented dissociation, hypertension, or mania.
case series Sample size: 4
This trial is ongoing; no results are reported in the abstract.
double-blind, placebo-controlled, randomized controlled trial Sample size: 60
Points of agreement
- Several studies explore glutamatergic or neuroplasticity-based interventions for PTSD, including ketamine, nitrous oxide, and dextromethorphan.
- Case reports and series suggest potential benefits from non-traditional interventions (yoga, dextromethorphan) but are limited by small samples and lack of controls.
- The survey study and case report highlight potential adverse psychiatric effects associated with psychedelic or MDMA use.
Conflicts
- The CAP-ketamine trial found no overall benefit of ketamine over placebo, while the case series on dextromethorphan reported positive effects, though these are different interventions.
- The survey study found that psychedelic experiences can lead to PTSD symptoms, whereas MDMA-assisted therapy is generally considered promising, but the case report shows a potential adverse outcome.
Gaps
- Durability of effects is not reported in most studies.
- Blinding is lacking in case studies and the survey.
- Sample sizes are small in case studies and the survey is self-selected.
- The THC augmentation trial is ongoing and no results are available.
- The ketamine trial's predictive model needs external validation.
- The nitrous oxide study is preclinical and requires human translation.